Physician profile
Yi Wang
NPI 1194222950
$1,495.09
in general payments reported to CMS, 2019-2025
22 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.08 · 2022: $423 · 2023: $219 · 2024: $250 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $996.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $348.89 | 2021-2025 | Breztri, Airsupra |
| Novo Nordisk INC | $203.73 | 2022-2025 | Wegovy |
| Lilly USA, LLC | $146.12 | 2021-2025 | Mounjaro, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.26 | 2022 | |
| Cranial Technologies, INC | $107.44 | 2022-2025 | Doc Band |
| Dexcom, INC. | $84.23 | 2021-2024 | Dexcom G6 Transmitter |
| Ultragenyx Pharmaceutical INC. | $58.61 | 2022-2024 | Crysvita |
| Pfizer INC. | $49.64 | 2023-2025 | |
| Dynavax Technologies Corporation | $49.60 | 2025 | Heplisav-B |
| Viiv Healthcare Company | $42.69 | 2022 | |
| Shield Therapeutics INC | $35.82 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.13 | 2022 | |
| Mayne Pharma Commercial LLC | $33.10 | 2024 | |
| Abbvie INC. | $25.48 | 2025 | |
| Exact Sciences Corporation | $24.70 | 2024 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $23.89 | 2023 | Shingrix, Bexsero |
| Kyowa Kirin, INC. | $22.59 | 2025 | |
| Sobi, INC | $21.78 | 2021 | |
| Sanofi Pasteur INC. | $19.34 | 2025 | |
| Supernus Pharmaceuticals, INC. | $18.39 | 2025 | Qelbree |
| Phathom Pharmaceuticals, INC. | $17.12 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $15.54 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yi Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.